Literature DB >> 17436000

Activin A suppresses interleukin-1-induced matrix metalloproteinase 3 secretion in human chondrosarcoma cells.

Deh-Ming Chang1, Shao-Hsiang Liu, Herng-Sheng Lee, Jenn-Hung Lai, Chen-Hung Chen.   

Abstract

The objective was to investigate the effect of activin A on matrix metalloproteinase 3 (MMP-3) production and to identify the role of activin A in chondroprotection. SW1353 cells, a human chondrosarcoma cell line, were stimulated with interleukin (IL) 1alpha and tumor necrosis factor (TNF) alpha, and the concentrations of activin A, follistatin, and MMP-3 secreted into the culture media were measured by enzyme-linked immunosorbent assay (ELISA). Activin A was added to cell cultures in the presence of IL-1alpha or TNFalpha to determine its effect on the production of MMP-3 and sulfated glycosaminoglycan (sGAG) (measured by Alcian blue assay). To study the mechanism responsible for the chondroprotective effects of activin A, the production of IL-1 receptor antagonist (IL-1ra) and tissue inhibitor for metalloproteinases 1 (TIMP-1) was examined by ELISA. Addition of IL-1alpha did not affect the production of activin A by cultured SW1353 cells. IL-1alpha and activin A inhibited the production of follistatin. Stimulation of SW1353 cells with activin A suppressed IL-1alpha-induced, but not TNFalpha-induced, MMP-3 expression. Activin A had no effect on the production of sGAG, IL-1ra, or TIMP-1, although it suppressed the induction of TIMP-1 and IL-1ra by IL-1alpha. This novel finding of MMP-3 inhibition by activin A suggests a new role of activin A in cartilage remodeling. Activin A may have therapeutic potential for preventing cartilage degradation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17436000     DOI: 10.1007/s00296-007-0350-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  40 in total

Review 1.  Expression of activin A in inflammatory arthropathies.

Authors:  R Gribi; T Tanaka; R Harper-Summers; J Yu
Journal:  Mol Cell Endocrinol       Date:  2001-06-30       Impact factor: 4.102

2.  Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.

Authors:  G Cunnane; O Fitzgerald; C Beeton; T E Cawston; B Bresnihan
Journal:  Arthritis Rheum       Date:  2001-10

3.  Local administration of activin promotes fracture healing in the rat fibula fracture model.

Authors:  R Sakai; K Miwa; Y Eto
Journal:  Bone       Date:  1999-08       Impact factor: 4.398

4.  Induced expression of the new cytokine, activin A, in human monocytes: inhibition by glucocorticoids and retinoic acid.

Authors:  J Yu; L E Shao; N L Frigon; J Lofgren; R Schwall
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

5.  Activin A stimulates type IV collagenase (matrix metalloproteinase-2) production in mouse peritoneal macrophages.

Authors:  K Ogawa; M Funaba; L S Mathews; T Mizutani
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

6.  Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis.

Authors:  C Ribbens; B Andre; J M Jaspar; O Kaye; M J Kaiser; D De Groote; M G Malaise
Journal:  J Rheumatol       Date:  2000-04       Impact factor: 4.666

7.  Interleukin-1 beta enhances and interferon-gamma suppresses activin A actions by reciprocally regulating activin A and follistatin secretion from bone marrow stromal fibroblasts.

Authors:  M Abe; Y Shintani; Y Eto; K Harada; Y Fujinaka; M Kosaka; T Matsumoto
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

8.  The role of IL-4 and IL-6 in IL-1-dependent cartilage matrix degradation.

Authors:  M Shingu; S Miyauchi; Y Nagai; C Yasutake; K Horie
Journal:  Br J Rheumatol       Date:  1995-02

9.  Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts.

Authors:  Ginette Tardif; David Hum; Jean-Pierre Pelletier; Christelle Boileau; Pierre Ranger; Johanne Martel-Pelletier
Journal:  Arthritis Rheum       Date:  2004-08

Review 10.  Follistatin: a multifunctional regulatory protein.

Authors:  D J Phillips; D M de Kretser
Journal:  Front Neuroendocrinol       Date:  1998-10       Impact factor: 8.606

View more
  3 in total

1.  Activin A: a potential therapeutic target for characterizing and stopping joint pain early in rheumatoid arthritis patients.

Authors:  Fei Dong; Xijing He
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

2.  Impact of TGF-β family-related growth factors on chondrogenic differentiation of adipose-derived stem cells isolated from lipoaspirates and infrapatellar fat pads of osteoarthritic patients.

Authors:  E López-Ruiz; G Jiménez; W Kwiatkowski; E Montañez; F Arrebola; E Carrillo; S Choe; J A Marchal; M Perán
Journal:  Eur Cell Mater       Date:  2018-04-13       Impact factor: 3.942

3.  Activin A/BMP2 chimera AB235 drives efficient redifferentiation of long term cultured autologous chondrocytes.

Authors:  G Jiménez; E López-Ruiz; W Kwiatkowski; E Montañez; F Arrebola; E Carrillo; P C Gray; J C Izpisua Belmonte; S Choe; M Perán; J A Marchal
Journal:  Sci Rep       Date:  2015-11-13       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.